Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 7,497,020 | 4,565,081 | 2,231,834 | 3,771,083 | 3,186,470 |
| Depreciation Amortization | 3,666,288 | 2,647,159 | 1,036,568 | 3,259,923 | 2,781,983 |
| Accounts receivable | N/A | N/A | N/A | 380,814 | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | -228,744 | N/A |
| Other Working Capital | -3,112,301 | -2,429,457 | -1,763,300 | 327,142 | 955,941 |
| Other Operating Activity | -687,429 | -454,103 | -62,975 | 865,138 | -1,429,359 |
| Operating Cash Flow | $7,363,578 | $4,328,680 | $1,442,127 | $8,375,356 | $5,495,035 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 14,827 | N/A | -27,709 | 2,905,945 | 2,990,079 |
| PPE Investments | -1,029,796 | -611,705 | -260,717 | -1,704,719 | -1,106,811 |
| Net Acquisitions | -2,268,516 | -1,107,212 | -1,008,859 | -1,106,661 | -989,757 |
| Purchase Of Investment | -70,091 | -60,102 | N/A | N/A | -54,625 |
| Sale Of Investment | 186,010 | 24,041 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -1,446,297 | -722,560 | -206,558 | -1,855,511 | -1,126,320 |
| Other Investing Activity | -1,280,504 | -607,699 | -143,584 | -1,665,104 | -981,952 |
| Investing Cash Flow | $-4,448,070 | $-2,362,677 | $-1,440,868 | $-1,570,539 | $-143,066 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 742,693 | 136,231 | 74,311 | 339,921 | -810,274 |
| Debt Issued | 2,667,494 | 2,648,495 | 2,541,671 | 1,373,743 | N/A |
| Debt Repayment | -1,889,756 | -1,881,860 | N/A | -2,063,809 | N/A |
| Common Stock Issued | 18,871 | 18,698 | 15,114 | 25,558 | 26,012 |
| Common Stock Repurchased | -1,516,387 | -1,079,165 | -311,097 | N/A | N/A |
| Dividend Paid | -2,585,272 | -1,693,541 | -770,814 | -3,123,188 | -2,382,699 |
| Other Financing Activity | -1,250,852 | -170,957 | -468,534 | -2,591,580 | -1,884,569 |
| Financing Cash Flow | $-3,813,209 | $-2,022,098 | $1,080,651 | $-6,039,355 | $-5,051,530 |
| Exchange Rate Effect | 29,654 | -49,417 | -13,855 | -69,007 | -79,337 |
| Beginning Cash Position | 4,586,904 | 4,545,047 | 4,286,079 | 3,652,238 | 3,717,115 |
| End Cash Position | 3,718,856 | 4,439,534 | 5,354,134 | 4,348,694 | 3,938,217 |
| Net Cash Flow | $-868,048 | $-105,512 | $1,068,056 | $696,456 | $221,102 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,363,578 | 4,328,680 | 1,442,127 | 8,375,356 | 5,495,035 |
| Capital Expenditure | -1,044,623 | -619,718 | -261,976 | -1,787,782 | -1,112,013 |
| Free Cash Flow | 6,318,955 | 3,708,962 | 1,180,151 | 6,587,574 | 4,383,022 |